Realizing the Value of Real World Evidence


Everyone knows real-world evidence (RWE) has value. But due to technology challenges, biopharma companies are struggling to achieve the full benefit of their RWE programs. Databricks recently surveyed 109 executives to get a better idea of what’s working, what’s not and the path forward.

Get the full results in this whitepaper. You’ll find out:

  • What benefits are driving investments in RWE programs
  • Which new types of real-world data will emerge in the next two years
  • The top factors inhibiting and contributing to RWE program success
  • How to build the ideal data architecture to unlock business outcomes with RWE

Read the Whitepaper

Yes, I would like to receive marketing communications

By submitting this form, my data will be handled according to Databricks’ Privacy Policy.